85 / 89
85
early diffuse systemic sclerosis trial. Arthritis
Rheum 2002;46:2983-9.
118.
Walker JG, Ahern MJ, Smith MD, Coleman M,
Pile K, Rischmueller M, et al. Scleroderma
renal crisis: poor outcome despite aggressive
antihypertensive treatment. Intern Med J
2003;33:216-20.
119.
Penn H, Howie AJ, Kingdon EJ, Bunn CC,
Stratton RJ, Black CM, et al. Scleroderma renal
crisis: patient characteristics and long-term
outcomes. QJM 2007;100:485-94.
120.
Teixeira L, Mouthon L, Mahr A, Berezné A,
Agard C, Mehrenberger M, et al. Mortality and
risk factors of scleroderma renal crisis: a
French retrospective study of 50 patients. Ann
Rheum Dis 2008;67:110-6.
121.
Hudson M, Baron M, Lo E, Weinfeld J, Furst
DE, Khanna D. An international, web-based,
prospective cohort study to determine whether
the use of ACE inhibitors prior to the onset of
scleroderma renal crisis is associated with
worse outcomes-methodology and preliminary
results. Int J Rheumatol. 2010;2010. pii: 347402.
doi: 10.1155/2010/347402. Epub 2010 Sep 14.
122.
Hesselstrand R, Scheja A, Wuttge D.
Scleroderma renal crisis in a Swedish systemic
sclerosis cohort: survival, renal outcome, and
RNA polymerase III antibodies as a risk factor.
Scand J Rheumatol 2012;41:39-43.
123.
Ferri C, Valentini G, Cozzi F, Sebastiani M,
Michelassi C, La Montagna G, et al. Systemic